Effects of maternal obesity on placental function and fetal development

Kristy R Howell1, Theresa L Powell2

  • 1Departments of PsychiatryObstetrics/Gynecology and Pediatrics, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.

Reproduction (Cambridge, England)
|November 20, 2016
PubMed

Insights

Maternal obesity impacts pregnancy, increasing risks for mothers and children. Adipokines and hormones alter placental function, affecting fetal development and long-term health outcomes in offspring.

Area of Science:

  • Reproductive Endocrinology
  • Developmental Biology
  • Metabolic Disease

Background:

  • Obesity is a global epidemic with significant implications for pregnancy.
  • Obesity in pregnancy increases risks for gestational diabetes, preeclampsia, and cesarean delivery.
  • Offspring of obese mothers face higher risks of childhood obesity, metabolic disorders, and neurodevelopmental issues.

Purpose of the Study:

  • To review how maternal obesity affects placental function through adipokines and metabolic hormones.
  • To explore the link between maternal obesity, placental changes, and long-term infant health.
  • To understand the mechanisms connecting maternal adiposity to fetal development and offspring health outcomes.

Main Methods:

  • Literature review focusing on adipokines (IL-6, TNF-α, leptin, adiponectin) and metabolic hormones.
  • Analysis of how these factors influence placental nutrient transport and vascularization.
  • Examination of studies linking maternal obesity to placental dysfunction and infant health.

Main Results:

  • Maternal adipokines and hormones directly impact placental function and nutrient delivery.
  • Obesity-associated placental changes, like reduced vascularity, can impair fetal growth.
  • Dysregulated placental function due to maternal obesity contributes to diverse short- and long-term infant health issues.

Conclusions:

  • Adipokines and metabolic hormones are key mediators linking maternal obesity to placental dysfunction.
  • Altered placental function in obese pregnancies has profound implications for fetal development and long-term child health.
  • Understanding these pathways is crucial for mitigating the adverse effects of maternal obesity on offspring.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.1K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
260
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
342